Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Shockwave Medical Inc's Business Segments
Shockwave Medical Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 219
Regions Reported
2
Shockwave Medical Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue Share by Region - FY
- Europe12%
- All Other Countries7.8%
Revenue by Geographic Region - FY
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| Europe | $ 26 | 12% |
| All Other Countries | $ 17 | 7.8% |
Revenue by Product & Service Category - FY
- Coronary75.3%
- Peripheral23.7%
- Reducer0.8%
- Product and Service, Other0.3%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Coronary | $ 165 | 75.3% |
| Peripheral | $ 52 | 23.7% |
| Reducer | $ 2 | 0.8% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
1 more categories available
Sign in to unlock the full Shockwave Medical Inc dataset.
Description of Shockwave Medical Inc
Shockwave Medical Inc. is a growing medical technology company based in Santa Clara, California, that aims to transform the way cardiovascular diseases are treated. The company specializes in developing products that employ a unique technology known as intravascular lithotripsy (IVL) to treat coronary and vascular calcified lesions.
Founded in 2009 by Dr. John Adams, the company has been successful in raising capital from well-known venture capitalists such as Norwest Venture Partners, Venrock, and Fidelity Management & Research Company, and has been listed on the NASDAQ under the ticker "SWAV" since March 2019. The company's mission is to develop innovative tools to disintegrate calcified arterial plaque, improving patient outcomes and quality of life.
Shockwave's technology, IVL, is a non-invasive, photoacoustic intravascular ultrasound-guided technique that utilizes sound waves to break down calcifications within arteries. The device uses an ultrasound probe to visualize the calcifications and deliver high-frequency sound waves to break them up into small particles that can be naturally eliminated by the body. This process differs from conventional treatment methods such as rotational atherectomy or laser atherectomy, which use a rotating blade or a laser to grind or vaporize plaque.
Shockwave's flagship device is the Shockwave Intravascular Lithotripsy System, which has received regulatory approval in the USA, Europe, and Japan. The device is approved for use in the treatment of severe coronary artery disease (CAD) and peripheral artery disease (PAD) in the lower legs. The Shockwave System has several benefits over conventional approaches to treating calcified lesions, including the ability to treat longer, more complex lesions with less injury to the artery walls and an improved safety profile due to a lower risk of perforation.
The company has amassed positive clinical trial data, including the DISRUPT PAD study, which demonstrated that the Shockwave System improved blood flow in more than 80% of patients with calcified PAD and that the benefits persisted at 12-month follow-up. Additionally, the DISRUPT CAD study suggested IVL was safe and effective in patients with calcified coronary lesions, with a low rate of procedural complications.
In recent years, the company has expanded its product pipeline, including the recent launch of the Shockwave S4 catheter, a next-generation version of the Shockwave Lithoplasty System. The company's sales have been increasing rapidly, and it continues to expand its geographical presence worldwide, with an increasing number of clinicians recognizing the benefits of the Shockwave System.
Overall, Shockwave Medical has established itself as a foremost leader in the field of cardiovascular disease treatment, with an innovative technology and a product portfolio that are poised to have significant impact on the treatment of patients with cardiovascular calcifications.
Founded in 2009 by Dr. John Adams, the company has been successful in raising capital from well-known venture capitalists such as Norwest Venture Partners, Venrock, and Fidelity Management & Research Company, and has been listed on the NASDAQ under the ticker "SWAV" since March 2019. The company's mission is to develop innovative tools to disintegrate calcified arterial plaque, improving patient outcomes and quality of life.
Shockwave's technology, IVL, is a non-invasive, photoacoustic intravascular ultrasound-guided technique that utilizes sound waves to break down calcifications within arteries. The device uses an ultrasound probe to visualize the calcifications and deliver high-frequency sound waves to break them up into small particles that can be naturally eliminated by the body. This process differs from conventional treatment methods such as rotational atherectomy or laser atherectomy, which use a rotating blade or a laser to grind or vaporize plaque.
Shockwave's flagship device is the Shockwave Intravascular Lithotripsy System, which has received regulatory approval in the USA, Europe, and Japan. The device is approved for use in the treatment of severe coronary artery disease (CAD) and peripheral artery disease (PAD) in the lower legs. The Shockwave System has several benefits over conventional approaches to treating calcified lesions, including the ability to treat longer, more complex lesions with less injury to the artery walls and an improved safety profile due to a lower risk of perforation.
The company has amassed positive clinical trial data, including the DISRUPT PAD study, which demonstrated that the Shockwave System improved blood flow in more than 80% of patients with calcified PAD and that the benefits persisted at 12-month follow-up. Additionally, the DISRUPT CAD study suggested IVL was safe and effective in patients with calcified coronary lesions, with a low rate of procedural complications.
In recent years, the company has expanded its product pipeline, including the recent launch of the Shockwave S4 catheter, a next-generation version of the Shockwave Lithoplasty System. The company's sales have been increasing rapidly, and it continues to expand its geographical presence worldwide, with an increasing number of clinicians recognizing the benefits of the Shockwave System.
Overall, Shockwave Medical has established itself as a foremost leader in the field of cardiovascular disease treatment, with an innovative technology and a product portfolio that are poised to have significant impact on the treatment of patients with cardiovascular calcifications.
Shockwave Medical Inc. is a pioneering medical device company that specializes in the development and commercialization of intravascular lithotripsy (IVL) technology specifically targeting calcified cardiovascular disease. The company has built its portfolio around innovative solutions designed to address the challenges posed by calcified arterial lesions, which can complicate common cardiovascular procedures.
Segments
1. Coronary Segment:
This segment is dedicated to the development of IVL devices that target calcified lesions within the coronary arteries. Calcification in coronary arteries is a significant contributor to coronary artery disease, leading to a higher risk of heart attacks. Shockwave Medicals innovations in this segment aim to facilitate safer and more effective treatment options for patients suffering from coronary artery disease.
2. Peripheral Segment:
The peripheral segment focuses on treating calcified lesions in the peripheral arteries, which can lead to conditions such as peripheral artery disease (PAD). These devices are developed to address the unique challenges of calcification in smaller, often more delicate peripheral arteries, providing a crucial solution to improve blood flow and reduce symptoms in affected patients.
Products
1. Shockwave IVL Catheters:
The core product line of Shockwave Medical consists of specialized IVL catheters that utilize sonic pressure waves to fracture calcified plaque. These catheters are designed to operate selectively, preserving healthy vascular tissue while effectively targeting and breaking down calcific deposits. This strategy is pivotal for treating patients with complex vascular anatomies.
2. Shockwave M5:
The Shockwave M5 is a next-generation system designed for enhanced control and precision in the application of sonic pressure waves. This system is versatile and can be utilized for both coronary and peripheral interventions, making it a robust addition to any interventional cardiologist’s toolkit. It offers advanced features that improve consistency and efficacy in treatment delivery.
3. Shockwave C2:
Tailored specifically for coronary applications, the Shockwave C2 catheter leverages customized shockwave energy to optimize lesion preparation. This device is engineered to ensure effective treatment of tightly or heavily calcified lesions in coronary arteries, thereby improving procedural outcomes.
4. Shockwave S4:
Targeting peripheral arterial disease, the Shockwave S4 catheter is renowned for delivering maximum lithotripsy power while maintaining a low-profile design. This compact size allows for easier navigation through complex peripheral vascular structures, which is essential for effective treatment and minimizing patient discomfort.
Services
1. Physician Training:
Shockwave Medical prioritizes physician training by providing comprehensive educational programs for healthcare professionals. Training sessions focus on the effective use of IVL technology, teaching advanced techniques and best practices to ensure that physicians are well-equipped to perform procedures confidently and competently.
2. Clinical Support:
The company offers extensive clinical support to healthcare providers, ensuring optimal outcomes when utilizing Shockwave’s IVL systems. This includes providing access to clinical resources, helping professionals navigate complex cases, and guiding them through best practices from initial treatment plans to post-procedure follow-ups.
3. Patient Education:
Understanding the importance of informed patients in the treatment process, Shockwave Medical provides educational materials aimed at patients. These resources help demystify the use of IVL technology and empower patients to make informed decisions regarding their vascular health and treatment options.
Summary
Shockwave Medical Inc. is focused on providing cutting-edge solutions for the treatment of calcified cardiovascular disease through its innovative IVL technology. With a strong emphasis on physician training, clinical support, and patient education, the company is dedicated to maximizing the efficacy of its products and ultimately improving patient care outcomes. By developing specific devices for both coronary and peripheral applications, Shockwave Medical continues to lead the way in addressing one of cardiology’s most challenging complications.
Segments
1. Coronary Segment:
This segment is dedicated to the development of IVL devices that target calcified lesions within the coronary arteries. Calcification in coronary arteries is a significant contributor to coronary artery disease, leading to a higher risk of heart attacks. Shockwave Medicals innovations in this segment aim to facilitate safer and more effective treatment options for patients suffering from coronary artery disease.
2. Peripheral Segment:
The peripheral segment focuses on treating calcified lesions in the peripheral arteries, which can lead to conditions such as peripheral artery disease (PAD). These devices are developed to address the unique challenges of calcification in smaller, often more delicate peripheral arteries, providing a crucial solution to improve blood flow and reduce symptoms in affected patients.
Products
1. Shockwave IVL Catheters:
The core product line of Shockwave Medical consists of specialized IVL catheters that utilize sonic pressure waves to fracture calcified plaque. These catheters are designed to operate selectively, preserving healthy vascular tissue while effectively targeting and breaking down calcific deposits. This strategy is pivotal for treating patients with complex vascular anatomies.
2. Shockwave M5:
The Shockwave M5 is a next-generation system designed for enhanced control and precision in the application of sonic pressure waves. This system is versatile and can be utilized for both coronary and peripheral interventions, making it a robust addition to any interventional cardiologist’s toolkit. It offers advanced features that improve consistency and efficacy in treatment delivery.
3. Shockwave C2:
Tailored specifically for coronary applications, the Shockwave C2 catheter leverages customized shockwave energy to optimize lesion preparation. This device is engineered to ensure effective treatment of tightly or heavily calcified lesions in coronary arteries, thereby improving procedural outcomes.
4. Shockwave S4:
Targeting peripheral arterial disease, the Shockwave S4 catheter is renowned for delivering maximum lithotripsy power while maintaining a low-profile design. This compact size allows for easier navigation through complex peripheral vascular structures, which is essential for effective treatment and minimizing patient discomfort.
Services
1. Physician Training:
Shockwave Medical prioritizes physician training by providing comprehensive educational programs for healthcare professionals. Training sessions focus on the effective use of IVL technology, teaching advanced techniques and best practices to ensure that physicians are well-equipped to perform procedures confidently and competently.
2. Clinical Support:
The company offers extensive clinical support to healthcare providers, ensuring optimal outcomes when utilizing Shockwave’s IVL systems. This includes providing access to clinical resources, helping professionals navigate complex cases, and guiding them through best practices from initial treatment plans to post-procedure follow-ups.
3. Patient Education:
Understanding the importance of informed patients in the treatment process, Shockwave Medical provides educational materials aimed at patients. These resources help demystify the use of IVL technology and empower patients to make informed decisions regarding their vascular health and treatment options.
Summary
Shockwave Medical Inc. is focused on providing cutting-edge solutions for the treatment of calcified cardiovascular disease through its innovative IVL technology. With a strong emphasis on physician training, clinical support, and patient education, the company is dedicated to maximizing the efficacy of its products and ultimately improving patient care outcomes. By developing specific devices for both coronary and peripheral applications, Shockwave Medical continues to lead the way in addressing one of cardiology’s most challenging complications.